Evolysse and Cold-X Review: The next-generation hyaluronic acid dermal filler
- Juvenology Clinic
- May 12
- 4 min read
Updated: 5 days ago
In February 2025, the first new hyaluronic acid filler in ten years received FDA approval. That gap matters. Hyaluronic acid fillers are one of the most studied product categories in aesthetic medicine. They work well, they are widely used, and the regulatory bar for proving meaningful clinical difference is high. A new product does not reach approval unless it demonstrates something that established options cannot.
Evolysse does that. Let me explain what it actually is, how the technology works, and what the clinical evidence shows.
Why hyaluronic acid structure matters
I want to channel my cardiac nurse brain for a moment, because understanding what makes Cold-X technology meaningful requires understanding what hyaluronic acid actually does in tissue.
Hyaluronic acid occurs naturally throughout the body. It is a sugar molecule that attracts water, up to 1,000 times its own weight. In your skin, it provides hydration and volume at the dermal level, acting as scaffolding that holds water where tissue needs plumpness and support. As we age, natural HA production falls. The dermis becomes dehydrated. Volume diminishes. Injectable HA fillers restore this by placing the water-attracting molecule back into the dermis, but there is a complication: natural HA breaks down in days. To create a filler that lasts months, manufacturers must crosslink the HA molecules, connecting them into a stable gel that resists rapid degradation.
The crosslinking process determines everything: how the filler feels, how it integrates with tissue, how long it lasts, and how natural it looks once in place. This is where Evolysse's technology becomes clinically interesting.
What Cold-X technology changes
Most HA fillers undergo crosslinking at room temperature or warmer. The process works, obviously. We have effective fillers with strong safety records developed this way. But the higher processing temperatures can fragment some of the natural HA chains during manufacturing, and more crosslinking agent is required to achieve stability.
Evolysse uses a process called Cold-X technology, developed by French manufacturer Symatese, which performs crosslinking at near-freezing temperatures. This preserves more of the natural long-chain HA structure rather than fragmenting it during processing. The result is a gel that requires less crosslinking agent, maintains more of HA's natural molecular architecture, and is designed to integrate more smoothly into tissue rather than sitting as a distinct foreign body within it.
The goal is not simply longevity. It is how naturally the filler behaves once it is in the skin, which is a different and more clinically meaningful target than durability alone.
What the clinical trial showed
Evolysse was tested in a randomised, double-blind, split-face trial comparing it directly against Restylane-L, one of the most widely used fillers in aesthetic medicine. Each patient received Evolysse on one side and Restylane-L on the other, meaning every comparison was made within the same person against the same anatomy, the same skin, and the same lifestyle factors. Only the product differed.
Evolysse Form, the firmer version designed for deeper folds, outperformed Restylane-L at every measured point across 12 months. Evolysse Smooth, the softer version for more superficial correction, showed better results at six and nine months and achieved those results using approximately 20% less product than the comparator. No treatment-related serious adverse events were reported. No delayed-onset nodules were seen with Evolysse.
That 20% efficiency finding is the detail I find most clinically significant. Achieving equivalent or superior correction with less product is not a minor commercial advantage. It means less material in the tissue, which matters for how the result feels and moves, and for the cumulative effect of maintenance treatments over time.
Form versus Smooth: how the choice is made
The two versions are not interchangeable and the decision between them is not a preference. It is anatomical.
Evolysse Form is a firmer gel suited to deeper placement and more substantial correction. It holds its shape more strongly and is designed for established folds where structural support is the primary requirement. Evolysse Smooth is a softer gel that spreads more easily through superficial tissue planes, suited to finer lines and subtler transitions where integration matters more than structure.
The choice depends on the depth of the fold, the thickness of the overlying skin, the degree of correction required, and what the anatomy will accommodate without looking treated. These are assessment decisions, not product preferences, and they are made at consultation after examining the face rather than in advance of it.
What the product cannot do
Evolysse is designed for moderate to severe facial folds, particularly the nasolabial region. It is not designed for lip augmentation, cheek volume restoration, jawline sculpting in isolation, or skin tightening. These require different products and different approaches, and conflating them does patients a disservice.
More importantly, no filler formulation changes the primacy of clinical judgement. Trials are conducted by experienced injectors in controlled conditions. Real-world outcomes depend on anatomical variation, knowledge of facial vasculature, injection depth, technique, and the ability to manage complications if they arise. Evolysse supports consistency in how the product behaves in tissue. It does not replace the assessment that determines where it goes, how much is placed, and whether it is the right choice at all.
At Juvenology, hyaluronidase is always immediately on site. Every dermal filler treatment includes a full facial assessment, vascular mapping, and a two-week review as standard.
The arrival of Evolysse is a refinement, not a revolution. The core principle has not changed: good results depend on anatomy, precision, and conservative placement. What has changed is the formulation science behind the product, with early clinical evidence suggesting that Cold-X technology produces a gel that integrates more naturally and performs more efficiently than the crosslinking methods that have dominated the category for the past decade.
About Me
I’m Nurse Marina, founder of Juvenology Clinic in Maidstone, Kent. I’ve been a nurse for 25 years, which probably explains why I’m obsessed with precision, safety, and understanding how the body works.
I’m an NMC Registered nurse, JCCP Verified, a BACN Member, ACE Group Registered, a member of the Royal College of Nursing, and recognised by the Professional Standards Authority.
If you want to see more of what I do day to day, I share education, clinic insights, and the occasional behind-the-scenes moment here.
Instagram: https://www.instagram.com/juvenologyclinic/